--- title: Stryker (SYK) — intrinsic value and fair price canonical: https://sweetvaluelab.com/stocks/syk ticker: SYK as_of: 2026-10-17 sector: Healthcare industry: Medical - Devices --- # Stryker (SYK) Stryker (SYK) closed at $294.66 on Oct 16, 2026, overvalued by 13% vs its model value of $261.75 (from a five-year discounted cash flow). ## Key figures | Figure | Value | | --- | ---: | | Last close | $294.66 (Oct 16, 2026) | | Model value (from a five-year discounted cash flow) | $261.75 | | Price vs model | overvalued by 13% vs model | | Range of that model | $157.06 – $677.77 | | Market value | $113.0B | | P/E (fiscal 2025) | 35.1 | | Net margin (fiscal 2025) | 12.9% | | Free cash flow (fiscal 2025) | $4.3B | | Dividend yield (trailing twelve months) | 1.19% | | Beta | 0.78 | | Cost of capital (WACC) | 8.01% | | Business classification | Mature & Stable (Moderate growth (~11% recent), Moderate margins (13% net margin), Pays dividends, Highly cyclical earnings) | ## Dividends | Figure | Value | | --- | ---: | | Trailing dividend yield | 1.19% | | Dividends per share, last 12 months | $3.52 | | Dividends / free cash flow (fiscal 2025) | 30.0% | | Raised | 16 years in a row | | Growth over 5 years | 6.9% a year | | Latest payment | $0.88, ex-date Sep 30, 2026, paid Oct 30, 2026 | | Year of payments | Dividends per share | | --- | ---: | | To Sep 29, 2021 | $2.52 | | To Sep 29, 2022 | $2.78 | | To Sep 28, 2023 | $3.00 | | To Sep 30, 2024 | $3.20 | | To Sep 30, 2025 | $3.36 | | Trailing twelve months (to Sep 30, 2026) | $3.52 | ## Valuation models Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026. | Model | Role | Value per share | Low | High | | --- | --- | ---: | ---: | ---: | | DCF · Perpetuity growth · 5y | primary | $261.75 | $157.06 | $677.77 | | DCF · Perpetuity growth · 10y | cross check | $296.54 | $182.57 | $744.22 | | DCF · EBITDA exit · 5y | cross check | $239.89 | $157.04 | $337.67 | | DCF · EBITDA exit · 10y | cross check | $275.77 | $182.12 | $401.26 | | P/E · peers | cross check | $225.35 | $210.72 | $230.76 | | P/E · own history | cross check | $520.94 | $481.91 | $560.52 | | PEG | sanity check | $351.72 | $351.72 | $351.72 | | EV/EBITDA · peers | cross check | $209.03 | $198.93 | $232.94 | | EV/Revenue · peers | cross check | $182.84 | $124.58 | $235.01 | | Earnings power value | cross check | $76.85 | $59.90 | $101.61 | | Dividend discount | cross check | $82.30 | $55.45 | $140.45 | ## Insider activity (SEC Form 4) Past 90 days: 0 open-market buys ($0) and 22 open-market sales ($118.2M); 10b5-1 plan sales included. | Date | Insider | Relationship | Transaction | Shares | Value | | --- | --- | --- | --- | ---: | ---: | | Sep 24, 2026 | Wells Preston Wendell | VP, Chief Financial Officer | Other | 109 | $0 | | Sep 22, 2026 | Wells Preston Wendell | VP, Chief Financial Officer | Other | 962 | $0 | | Jul 17, 2026 | Wells Preston Wendell | VP, Chief Financial Officer | Other | 1,776.804 | $0 | | Jun 26, 2019 | BRAINERD MARY K | Director | Open-market buy | 63 | $12,738.9 | | Sep 12, 2019 | BRAINERD MARY K | Director | Open-market buy | 11 | $2,431.3 | ## Recent SEC filings | Filed | Form | What | Filing | | --- | --- | --- | --- | | Oct 6, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/310764/000119312526414956/d84795d8k.htm | | Jul 31, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/310764/000031076426000050/syk-20260630.htm | | Jul 30, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/310764/000031076426000048/syk-20260730.htm | | Jun 26, 2026 | 8-K | 8.01 Other Events; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/310764/000031076426000041/syk-20260626.htm | | May 20, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/310764/000119312526232643/d51680d8k.htm | ## Superinvestors holding it (latest 13F) | Manager | Quarter | Shares | Value | | --- | --- | ---: | ---: | | Terry Smith | 2026-06-30 | 2,913,833 | $917.4M | | Jensen | 2026-06-30 | 589,670 | $185.7M | | AKO Capital | 2026-06-30 | 20,624 | $6.5M | | Bridgewater | 2026-06-30 | 12,155 | $3.8M | 5 tracked managers in all. ## About Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, caterin… --- Source: https://sweetvaluelab.com/stocks/syk (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.